1. Home
  2. Live Updates
  3. Data from Across Incyte's Oncology Portfolio Accepted for Pr

Data from Across Incyte's Oncology Portfolio Accepted for Pr

Data from Across Incyte's Oncology Portfolio Accepted for Presentation at the 2023 ASCO Annual Meeting and EHA2023 Hybrid Congress Seite 1

25.05.2023 - Incyte (Nasdaq:INCY) today announced that multiple abstracts featuring data from across its oncology portfolio will be presented at the upcoming 2023 American Society of Clinical Oncology (ASCO) Annual Meeting held June 2-6 in Chicago, and at the ... Seite 1

Related Keywords

, Activin Receptor Like Kinase , Hematologic Malignancies , Myelodysplastic Syndromes , Open Label Study , Add On Therapy , Suboptimal Response , Incyte ,

© 2025 Vimarsana